Zosano Appoints Kenneth Greathouse to Board of Directors
October 04 2017 - 9:00AM
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the
“Company”), a clinical-stage biopharmaceutical company focused on
providing rapid systemic administration of therapeutics to patients
using our proprietary ADAM technology, announced today that Mr.
Kenneth R. Greathouse has been appointed to the Board of Directors.
"We are pleased to have Ken joining us at such an important
stage for the Company," commented John Walker, Chief Executive
Officer and Chairman of the Board. “Ken’s commercial
experience in the field of neurology will provide Zosano with
leadership and insight as we progress M207 towards the market.”
“I am pleased to join the Board,” commented Mr.
Greathouse. “I look forward to working with the management
team and Board as our lead program progresses towards an NDA filing
and, if approved, towards commercialization.”
Kenneth R. Greathouse is a seasoned pharmaceutical
executive with over 40 years of experience in sales, marketing,
business development and commercial operations. He is the
co-founder of several successful drug development companies,
including Manchester Pharmaceuticals which was sold to Retrophin
Inc. in 2014. He began his career with Lederle Laboratories
where for over 18 years he held a number of sales and marketing
positions of increasing responsibility. He joined Athena
Neurosciences in 1993 and continued with Elan Pharmaceuticals after
the acquisition of Athena. After a two year tenure at Boron
LePore and Associates as Vice President and General Manager of
Contract Sales, he joined Questcor as Senior Vice President,
Commercial Operations. Since leaving Questcor, Mr. Greathouse
has co-founded and served as CEO of Argent Development Group LLC,
Melbourne Laboratories LLC, Valcrest Pharmaceuticals LLC, and
Hesperian BioPharma LLC, in addition to Manchester Pharmaceuticals
LLC.
About Zosano Pharma Zosano Pharma Corporation
is a clinical stage biopharmaceutical company focused on providing
rapid systemic administration of therapeutics to patients using our
proprietary Adhesive Dermally-Applied Microarray, or ADAM
technology. The Company recently announced positive results
from our ZOTRIP study that evaluated M207, which is our proprietary
formulation of zolmitriptan delivered via our ADAM technology, as
an acute treatment for migraine. Zosano is focused on
developing products where rapid administration of established
molecules with known safety and efficacy profiles provides an
increased benefit to patients, for markets where patients remain
underserved by existing therapies. The Company anticipates that
many of its current and future development programs may enable the
Company to utilize a regulatory pathway that would streamline
clinical development and accelerate the path towards
commercialization. Learn more
at www.zosanopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding
the timing of expected clinical development milestones, sufficiency
of our capital resources and need for future funding and other
future events and expectations. Readers are urged to consider
statements that include the words "may," "will," "would," "could,"
"should," "might," "believes," "estimates," "projects,"
"potential," "expects," "plans," "anticipates," "intends,"
"continues," "forecast," "designed," "goal," "unaudited,"
"approximately" or the negative of those words or other comparable
words to be uncertain and forward-looking. These statements are
subject to risks and uncertainties that are difficult to predict
and actual outcomes may differ materially. These include risks and
uncertainties, without limitation, associated with the process of
discovering, developing and commercializing products that are safe
and effective for use as human therapeutics, risks inherent in the
effort to build a business around such products and other risks and
uncertainties described under the heading "Risk Factors" in the
Company's most recent annual report on Form 10-K.. Although we
believe that the expectations reflected in these forward-looking
statements are reasonable, we cannot in any way guarantee that the
future results, level of activity, performance or events and
circumstances reflected in forward-looking statements will be
achieved or occur. All forward-looking statements are based on
information currently available to Zosano and Zosano assumes no
obligation to update any such forward-looking statements.
Zosano Contact:Georgia ErbezChief Business
Officer and Chief Financial Officer510-745-1200
Zosano Pharma (NASDAQ:ZSAN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zosano Pharma (NASDAQ:ZSAN)
Historical Stock Chart
From Apr 2023 to Apr 2024